These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 22311607)

  • 1. Antibodies for prevention and treatment of respiratory syncytial virus infections in children.
    Geevarghese B; Simões EA
    Antivir Ther; 2012; 17(1 Pt B):201-11. PubMed ID: 22311607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis.
    Groothuis JR; Hoopes JM; Hemming VG
    Adv Ther; 2011 Feb; 28(2):110-25. PubMed ID: 21318605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Respiratory syncytial virus disease: update on treatment and prevention.
    Krilov LR
    Expert Rev Anti Infect Ther; 2011 Jan; 9(1):27-32. PubMed ID: 21171875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
    Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New strategies for control of respiratory syncytial virus infection.
    Nokes JD; Cane PA
    Curr Opin Infect Dis; 2008 Dec; 21(6):639-43. PubMed ID: 18978532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Respiratory syncytial virus immunoglobulin and monoclonal antibodies in the prevention and treatment of respiratory syncytial virus infection.
    Welliver RC
    Semin Perinatol; 1998 Feb; 22(1):87-95. PubMed ID: 9523402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and pharmacological aspects of immunoprophylaxis for respiratory syncytial virus infection in high-risk infants.
    Lanari M; Silvestri M; Rossi GA
    Curr Drug Metab; 2013 Feb; 14(2):216-25. PubMed ID: 22935064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infection by the respiratory syncytial virus in infants and young children at high risk.
    Bonnet D; Schmaltz AA; Feltes TF
    Cardiol Young; 2005 Jun; 15(3):256-65. PubMed ID: 15865827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention and treatment of respiratory syncytial virus infection in infants: an update.
    Venkatesh MP; Weisman LE
    Expert Rev Vaccines; 2006 Apr; 5(2):261-8. PubMed ID: 16608425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.
    Groothuis JR; Simoes EA; Levin MJ; Hall CB; Long CE; Rodriguez WJ; Arrobio J; Meissner HC; Fulton DR; Welliver RC
    N Engl J Med; 1993 Nov; 329(21):1524-30. PubMed ID: 8413475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Respiratory Syncytial Virus Immune Globulin Study Group.
    Groothuis JR; Simoes EA; Hemming VG
    Pediatrics; 1995 Apr; 95(4):463-7. PubMed ID: 7700741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease.
    Cabalka AK
    Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S41-5. PubMed ID: 14730269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Humanized respiratory syncytial virus monoclonal antibody].
    Tsutsumi H
    Nihon Rinsho; 2002 Mar; 60(3):487-91. PubMed ID: 11904963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoprophylaxis and immunotherapy of respiratory syncytial virus-infected mice with respiratory syncytial virus-specific immune serum.
    Graham BS; Davis TH; Tang YW; Gruber WC
    Pediatr Res; 1993 Aug; 34(2):167-72. PubMed ID: 8233720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palivizumab in the prophylaxis of respiratory syncytial virus infection.
    Cardenas S; Auais A; Piedimonte G
    Expert Rev Anti Infect Ther; 2005 Oct; 3(5):719-26. PubMed ID: 16207163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
    Hashmi NA; Cosgrove JF; MacMahon P
    Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Respiratory syncytial virus infections: recent prospects for control.
    Sidwell RW; Barnard DL
    Antiviral Res; 2006 Sep; 71(2-3):379-90. PubMed ID: 16806515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Palivizumab--a monoclonal antibody for passive immunoprophylaxis of respiratory syncytial virus infections].
    Scholz H
    Z Geburtshilfe Neonatol; 2000; 204(3):120-2. PubMed ID: 10909169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention strategies for respiratory syncytial virus: passive and active immunization.
    Englund JA
    J Pediatr; 1999 Aug; 135(2 Pt 2):38-44. PubMed ID: 10431138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.